Following the failure of tecemotide (formerly known as Stimuvax) in a Phase I/II study in Japanese patients, Merck has decided to discontinue all clinical development of the drug, including the Phase III START2 and INSPIRE non-small cell lung cancer trials. Tecemotide is a MUC1 antibody-specific immunotherapy licensed from biotech company Oncothyreon. It had previously failed […]
RTRX – In a Consolidation Mode
Retrophin, Inc. (RTRX) –Nasdaq During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]
April 14 Biotech Update-
It was a really slow day on the news front, which could simply relate to the start of a pre-holiday week. I did not think it would extend all the way to today but so far nothing major happening in the sector. I will touch on a couple of ideas but will keep this short […]
RTRX – Notes on Retrophin’s PKAN program
August was a month full of news for Retrophin (RTRX): financing, PR on preclinical results of their PKAN candidate (RE-024), PR on agreement to negotiate a candidate for autism and schizophrenia. In addition, rumors came out on Alexion making an offer for $10 a share, motivated by the strong preclinical results of RE-024. All this […]
August 16- EOD (kind of)
This is a Friday in August and so it is not surprising that it was light on the news front as well as it being another low volume chop fest. That being said biotechs seemed to be getting their footing more so than earlier in the week but it is still very difficult to tell […]
JPM13, Biotech Showcase: Management Meetings
Notes From The Conference ImmunoCellular Therapeutics (NYSE MKT:IMUC) Met with Peter Ho, former scientist and analyst, now Director of Business Development at Immunocellular Therapeutics. According to Ho, the reason for previous CEO Singh’s departure was a difference in vision for the company between him and the board; he was aiming for a sale while board […]
RTRX – Retrophin- From Hedgefund to Biotech
Introduction Started in 2010 as an “extracurricular activity” by hedge fund manager Martin Shkreli, Retrophin was officially formed in February 2011 to focus on developing drugs for orphan indications. The current pipeline consists of a single compound in Phase II along with three preclinical projects. It went public in December 2012 through a reverse merger […]
